Hansen Christine Krarup, Christensen Anders, Havsteen Inger, Ovesen Christian, Christensen Hanne
Department of Neurology, Bispebjerg Hospital, Copenhagen, Denmark.
Department of Radiology, Bispebjerg Hospital, Copenhagen, Denmark.
Clin Neurol Neurosurg. 2018 Aug;171:58-62. doi: 10.1016/j.clineuro.2018.05.003. Epub 2018 May 5.
Early Neurological Deterioration (END) occur in up to 25% of patients with ischaemic stroke receiving stroke-unit-care and in 11-13.8% of patients treated with iv-tissue-Plasmniogen-Activator (iv-tPA). The aim of the study was to establish and compare the prevalence of END and symptomatic Intracranial Hemorrhage (sICH) in a prospectively designed registry of consecutive patients treated with iv-tPA to a historic cohort of iv-tPA eligible patients whom were hospitalized prior to implementation of iv-tPA-treatment but receiving otherwise comparable acute stroke care.
Single center registry from a public Danish stroke-unit. Three-hundred-sixty-one unselected consecutive iv-tPA-treated patients admitted within 4.5 h from symptom-onset with symptoms of acute stroke and >17 years of age. The iv-tPA-treated cohort was compared to a pre-tPA cohort of 246 iv-tPA-eligible patients who were admitted to the same stroke center from 1998 to 2001. Acute stroke care apart from iv-tPA was comparable. Outcome measures was assessed on admission and at 24 h; END as any increase in National Institute of Health Stroke Scale (NIHSS) and symptomatic Intracranial Hemorrhage (sICH) with use of CT-head-scan.
END was observed in 27 (7.5%) of the 361 patients in the tPA-cohort and 43 (17.5%) of 246 in the pre-tPA-cohort, p < 0.0001. Any ICH was detected in 23 (6.4%) and sICH in 3 (0.8%) of the iv-tPA-treated patients.
END is significantly less frequent in acute stroke patients treated with iv-tPA. Deterioration due to ICH was rare and of limited severity in this population. END though remains a significant complication after stroke why more detailed knowledge on the various causes of END is needed to further improve patient outcome.
在接受卒中单元治疗的缺血性卒中患者中,高达25%会发生早期神经功能恶化(END),在接受静脉注射组织型纤溶酶原激活剂(iv-tPA)治疗的患者中,这一比例为11%-13.8%。本研究的目的是在前瞻性设计的连续接受iv-tPA治疗的患者登记册中,确定并比较END和症状性颅内出血(sICH)的患病率,并与iv-tPA治疗资格患者的历史队列进行比较,这些患者在iv-tPA治疗实施之前住院,但接受了其他可比的急性卒中治疗。
来自丹麦一家公立卒中单元的单中心登记册。361例未经选择的连续接受iv-tPA治疗的患者,在症状发作后4.5小时内入院,有急性卒中症状且年龄大于17岁。将接受iv-tPA治疗的队列与1998年至2001年期间入住同一卒中中心的246例符合iv-tPA治疗条件的患者的tPA前队列进行比较。除iv-tPA外,急性卒中治疗具有可比性。在入院时和24小时时评估结局指标;END定义为美国国立卫生研究院卒中量表(NIHSS)的任何增加,以及使用头颅CT扫描诊断的症状性颅内出血(sICH)。
tPA队列的361例患者中有27例(7.5%)发生END,tPA前队列的246例患者中有43例(17.5%)发生END,p<0.0001。在接受iv-tPA治疗的患者中,23例(6.4%)检测到任何颅内出血,3例(0.8%)检测到症状性颅内出血。
接受iv-tPA治疗的急性卒中患者中END的发生率显著较低。在该人群中,因颅内出血导致的病情恶化很少见且严重程度有限。尽管如此,END仍然是卒中后的一个重要并发症,因此需要更详细地了解END的各种原因,以进一步改善患者的预后。